Journal article
Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice
Amabel CL Tan, Edin J Mifsud, Weiguang Zeng, Kathryn Edenborough, Jodie McVernon, Lorena E Brown, David C Jackson
MOLECULAR PHARMACEUTICS | AMER CHEMICAL SOC | Published : 2012
DOI: 10.1021/mp300257x
Abstract
The protective role played by the innate immune system during early stages of infection suggests that compounds which stimulate innate responses could be used as antimicrobial or antiviral agents. In this study, we demonstrate that the Toll-like receptor-2 agonist Pam2Cys, when administered intranasally, triggers a cascade of inflammatory and innate immune signals, acting as an immunostimulant by attracting neutrophils and macrophages and inducing secretion of IL-2, IL-6, IL-10, IFN-γ, MCP-1 and TNF-α. These changes provide increased resistance against influenza A virus challenge and also reduce the potential for transmission of infection. Pam2Cys treatment also reduced weight loss and letha..
View full abstractGrants
Funding Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia.